Morepen Proposes Dividend After 23 Years, Logs Rs 1.18 Bn PAT in FY25

14 May 2025 CW Team

The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.

Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”

Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.

Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

In a landmark announcement that signals a new era of growth and financial strength, Morepen Laboratories board has proposed to declared a dividend (₹0.20 per share) after a gap of 23 years, marking a defining moment in the company’s four-decade legacy, subject to approval of the shareholders in the forthcoming Annual General Meeting.The declaration comes on the back of excellent financial results for FY25, with gross revenue rising to Rs 18.30 billion, up from Rs 17.04 billion in FY24 — a 7.4 per cent year-on-year increase. EBITDA surged 11.5 per cent to Rs 1.92 billion, and Profit After Tax jumped to Rs 1.18 billion, while Earnings Per Share (EPS) climbed to Rs 2.20, up 17 per cent from the previous year.Sushil Suri, Chairman & Managing Director of Morepen Laboratories, said: “This moment is symbolic – it’s not just about distributing profits; it’s about rewarding trust. We always believe in the “Joy of Growing Together”. Declaring a dividend after 23 years reflects our financial strength, operational excellence, and long-term vision of sharing and caring. Our shareholders have stood by us, and it’s time we give back.”Morepen’s API business continued to dominate, contributing Rs 9.89 billion, while the Medical Devices segment surged to Rs 4.96 billion, growing 12 per cent year-on-year. With 72 per cent of API revenue coming from exports across 80+ countries, Morepen is solidifying its position as a global pharmaceutical force. Investments in new product development, capacity expansion, and global regulatory approvals continue to propel the business forward.Morepen Laboratories Ltd. is a vertically integrated, innovation-led pharmaceutical and healthcare company delivering high- quality APIs, branded generics, medical devices, and consumer wellness products to over 80 countries worldwide. With an installed API capacity of 514 KL, a 14 million-strong glucometer user base, and a rapidly expanding digital footprint, Morepen stands at the forefront of India's health-tech evolution. Backed by decades of trust, regulatory approvals from USFDA, WHO, and EU bodies, and a passion for innovation, Morepen is committed to making quality healthcare accessible, affordable, and future-ready.

Infrastructure Urban

09 Jan 2026

Mount Invests Rs 250 Cr, Adds PUF & PEB Plants, 400+ Jobs

TUMKUR, Karnataka, January 8, 2025 - Mount Roofing & Structures Private Limited, one of India's fastest-growing manufacturers in PUF and a leading solutions provider across Pre-Engineered Building (PEB) and Polycarbonate sheets, simultaneously inaugurated its second fully automated continuous Sandwich Panel manufacturing line and a new PEB manufacturing plant at its integrated campus in Tumkur." The milestone expansion, part of a total investment of INR 250 crores, marks a significant advancement in the company's commitment to engineered performance, manu..

Infrastructure Urban

09 Jan 2026

Titan Intech Strengthens UltraLED Push With Global LED Veteran

Titan Intech has announced the induction of global LED industry veteran Su Piow Ko to its Board of Directors, marking a strategic step in strengthening its UltraLED Displays roadmap and building globally competitive LED display solutions from India.The appointment aligns with Titan Intech’s ambition to position India as a hub for advanced, high-quality LED display manufacturing. With an increased focus on UltraLED Displays, the company aims to enhance technical governance, raise manufacturing standards and expand its presence across global markets.Su Piow Ko brings over three decades of inte..

Infrastructure Urban

09 Jan 2026

Dun & Bradstreet Flags New Growth Engines in India 2026 Outlook

Dun & Bradstreet has released its India 2026: D&B’s Perspective report, projecting a stable macroeconomic environment underpinned by fresh opportunities for productivity-led and inclusive growth. The report outlines how India’s next growth phase will be driven by digitised logistics, trusted data ecosystems, clean energy and rising city vitality.According to the outlook, India’s GDP growth is expected to reach around 6.6 per cent by FY2027, supported by resilient consumer demand and sustained public investment. Manufacturing is seen entering a new phase, moving beyond scale towar..